Ascom has signed up SEC-COM to become a new distribution partner in Germany
The two technology providers have signed a multimillion-euro framework contract of Ascom solutions.
SEC-COM Security and Communication Technology GmbH is one of the leading IT and telecommunication providers in Germany, with very strong consulting expertise and focus on future technologies.
The framework agreement with Ascom covers the entire product range, including mobility solutions (IP DECT / i63 / Myco 4), clinical alarm software (Unite / Ofelia), and nurse call systems (teleCARE IP / telligence). The collaboration strengthens the position of both companies in the German healthcare market and drives digitalization in nursing homes and clinics.
Guido Otterbein, Managing Director of SEC-COM, explains: 'SEC-COM develops solutions in collaboration with customers to facilitate work processes and improve safety. Ascom pursues a similar goal, providing products and solutions characterized by quality and expertise. Together, innovations for the German healthcare system are to be supported.'
Nicolas Vanden Abeele, Chief Executive Officer of Ascom, states: 'We are pleased with the new partnership between SEC-COM and Ascom. This partnership enhances communication and workflow efficiency in the German healthcare sector, benefiting patients and caregivers and further strengthens Ascom's position as a leading provider in critical communication and collaboration in the German healthcare market.'
Attachment
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Politico
2 hours ago
- Politico
Trump tells European leaders he'll continue Russia talks through in-person meetings with Putin
The New York Times previously reported on the plan for the meeting, which the Times said will occur as soon as next week. The German official did not provide any details on the timing of the planned meetings. The White House has not confirmed such a proposal was outlined with the European leaders. Earlier Wednesday, White House spokesperson Karoline Leavitt said Trump remained open to the prospect of meeting with Putin, but declined to say whether such a proposal was outlined in the phone call. Putin met with Trump's special envoy Steve Witkoff in Moscow earlier Wednesday and Trump described that three-hour meeting at the Kremlin as 'highly productive.' It's unclear what the planned meeting with Putin means for Trump's Friday deadline for imposing sanctions against countries who purchase Russian energy – which he has said he will do to punish Moscow if it doesn't make more progress towards a peaceful end to the war in Ukraine. The White House did not immediately respond to a request for comment on the European leaders' call. Trump pledged to end the war in Ukraine 'on day one' of his second presidency. But Russia has stymied peace talks, infuriating both Ukrainian and American negotiators by continuing to conduct airstrikes on civilian targets in Ukraine. Trump threatened in July to impose hefty new sanctions and secondary measures to punish the Russian economy, targeting oil sales that have allowed it to stay economically afloat despite becoming a global economic pariah since the invasion.
Business Wire
3 hours ago
- Business Wire
CRH plc (the "Company") Form 10-Q for the quarterly period ended June 30, 2025
NEW YORK--(BUSINESS WIRE)--A Form 10-Q for the quarterly period ended June 30, 2025 (the 'Form 10-Q') has been filed with the U.S. Securities and Exchange Commission (the "SEC") today. The Form 10-Q is available to view on the SEC's website at: and the Company's website at: https://
Business Wire
3 hours ago
- Business Wire
CareDx Announces Appointment of Nathan Smith as Chief Financial Officer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced the appointment of Nathan Smith to the role of Chief Financial Officer. Nathan will lead key financial and accounting initiatives that are a part of the Company's long-term strategic growth plan. Nathan brings more than 14 years of experience in the molecular diagnostics industry, including senior finance leadership roles at Myriad Genetics and recent CFO positions at Blackrock Neurotech and WIN Brands. 'Nathan's deep financial expertise in molecular diagnostics is a great fit for CareDx,' said John Hanna, CEO of CareDx. 'His track record of operational excellence and experience in supporting diagnostics companies to scale efficiently will be invaluable as we enter our next phase.' In conjunction with this appointment, the Company also announced that Abhishek Jain will be retiring from his role as Chief Financial Officer. Abhishek will continue to support CareDx in a consulting capacity to ensure a seamless transition. 'On behalf of the Board and the entire CareDx team, I want to express my sincere gratitude to Abhishek for his outstanding leadership as CFO,' said John Hanna. 'Abhishek's disciplined financial management, stewardship through our CEO transition, and dedication to strengthening our finance function have positioned CareDx for continued success. We wish him all the best.' About CareDx CareDx, Inc., headquartered in Brisbane, California, is a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. For more information, visit Forward Looking Statements This press release includes forward-looking statements related to CareDx, Inc. These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including general economic and market factors and other risks discussed in CareDx's filings with the SEC, including, but not limited to, the Annual Report on Form 10-K for the fiscal year ended December 31, 2024 filed by CareDx with the SEC on February 28, 2025, the Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed by CareDx with the SEC on April 30, 2025, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
